These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

692 related items for PubMed ID: 12481412

  • 1. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.
    Krystal GW, Sulanke G, Litz J.
    Mol Cancer Ther; 2002 Sep; 1(11):913-22. PubMed ID: 12481412
    [Abstract] [Full Text] [Related]

  • 2. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
    Warshamana-Greene GS, Litz J, Buchdunger E, García-Echeverría C, Hofmann F, Krystal GW.
    Clin Cancer Res; 2005 Feb 15; 11(4):1563-71. PubMed ID: 15746061
    [Abstract] [Full Text] [Related]

  • 3. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.
    Warshamana-Greene GS, Litz J, Buchdunger E, Hofmann F, García-Echeverría C, Krystal GW.
    Mol Cancer Ther; 2004 May 15; 3(5):527-35. PubMed ID: 15141010
    [Abstract] [Full Text] [Related]

  • 4. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
    Krystal GW, Honsawek S, Litz J, Buchdunger E.
    Clin Cancer Res; 2000 Aug 15; 6(8):3319-26. PubMed ID: 10955819
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J, West KA, Sayyah J, Gills JJ, Dennis PA.
    Cancer Res; 2005 Sep 15; 65(18):8423-32. PubMed ID: 16166321
    [Abstract] [Full Text] [Related]

  • 6. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
    Martelli AM, Tazzari PL, Tabellini G, Bortul R, Billi AM, Manzoli L, Ruggeri A, Conte R, Cocco L.
    Leukemia; 2003 Sep 15; 17(9):1794-805. PubMed ID: 12970779
    [Abstract] [Full Text] [Related]

  • 7. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.
    Thimmaiah KN, Easton J, Huang S, Veverka KA, Germain GS, Harwood FC, Houghton PJ.
    Cancer Res; 2003 Jan 15; 63(2):364-74. PubMed ID: 12543789
    [Abstract] [Full Text] [Related]

  • 8. Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer.
    Maulik G, Madhiwala P, Brooks S, Ma PC, Kijima T, Tibaldi EV, Schaefer E, Parmar K, Salgia R.
    J Cell Mol Med; 2002 Jan 15; 6(4):539-53. PubMed ID: 12611639
    [Abstract] [Full Text] [Related]

  • 9. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.
    Clark AS, West K, Streicher S, Dennis PA.
    Mol Cancer Ther; 2002 Jul 15; 1(9):707-17. PubMed ID: 12479367
    [Abstract] [Full Text] [Related]

  • 10. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
    Pfeil K, Eder IE, Putz T, Ramoner R, Culig Z, Ueberall F, Bartsch G, Klocker H.
    Prostate; 2004 Feb 15; 58(3):259-68. PubMed ID: 14743465
    [Abstract] [Full Text] [Related]

  • 11. Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2.
    Song K, Cornelius SC, Reiss M, Danielpour D.
    J Biol Chem; 2003 Oct 03; 278(40):38342-51. PubMed ID: 12876289
    [Abstract] [Full Text] [Related]

  • 12. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
    Kijima T, Maulik G, Ma PC, Tibaldi EV, Turner RE, Rollins B, Sattler M, Johnson BE, Salgia R.
    Cancer Res; 2002 Nov 01; 62(21):6304-11. PubMed ID: 12414661
    [Abstract] [Full Text] [Related]

  • 13. Phosphatidylinositol 3-kinase (PI-3K)/Akt but not PI-3K/p70 S6 kinase signaling mediates IGF-1-promoted lens epithelial cell survival.
    Chandrasekher G, Sailaja D.
    Invest Ophthalmol Vis Sci; 2004 Oct 01; 45(10):3577-88. PubMed ID: 15452065
    [Abstract] [Full Text] [Related]

  • 14. p38 MAPK mediates gamma-irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway.
    Kumar P, Miller AI, Polverini PJ.
    J Biol Chem; 2004 Oct 08; 279(41):43352-60. PubMed ID: 15292252
    [Abstract] [Full Text] [Related]

  • 15. Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
    Nguyen DM, Chen GA, Reddy R, Tsai W, Schrump WD, Cole G, Schrump DS.
    J Thorac Cardiovasc Surg; 2004 Feb 08; 127(2):365-75. PubMed ID: 14762343
    [Abstract] [Full Text] [Related]

  • 16. Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance.
    Thakkar H, Chen X, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK.
    J Biol Chem; 2001 Oct 19; 276(42):38361-9. PubMed ID: 11461904
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway.
    Zhang J, Choi Y, Mavromatis B, Lichtenstein A, Li W.
    Oncogene; 2003 Sep 18; 22(40):6289-95. PubMed ID: 13679867
    [Abstract] [Full Text] [Related]

  • 20. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.
    Brognard J, Clark AS, Ni Y, Dennis PA.
    Cancer Res; 2001 May 15; 61(10):3986-97. PubMed ID: 11358816
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.